Jabbarpoor Bonyadi Mohammad Hossein, Yaseri Mehdi, Nikkhah Homayoun, Bonyadi Mortaza, Nazari Rahman, Soheilian Masoud
Ocular Tissue Engineering Research Center, Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Biostatistics and Epidemiology, Tehran University of Medical Sciences, Tehran, Iran.
Int Ophthalmol. 2019 Apr;39(4):949-956. doi: 10.1007/s10792-018-0853-y. Epub 2018 Feb 8.
We designed this meta-analysis to pool studies which have analyzed both CFH (Y402H or I62V) and ARMS2 A69S in the same samples to compare the effect of CFH and ARMS2 in neovascular AMD.
Relevant studies identified and reviewed separately in order to select those for inclusion. Included studies had genotype data of studied groups for both ARMS2 A69S and CFH. To modify the heterogeneity in the variables, we used random effects model. Meta-analysis was performed using STATA. Funnel plot and Egger's regression test used for evaluation of the possible publication bias.
Overall, we included 6676 neovascular AMD cases and 7668 controls. Pooled overall odds ratios (ORs) (95% CI) for neovascular AMD/control were ARMS2 A69S: OR = 2.35 (2.01-2.75) for GT versus GG; OR = 8.57 (6.91-10.64) for TT versus GG; CFH Y402H: OR = 1.94 (1.73-2.18) for CT versus TT; OR = 4.89 (3.96-6.05) for CC versus TT. ARMS2 A69S genotype OR/CFH Y402H genotype OR (homogeneous genotypes): Asia = 2.14, Europe: 1.87, America: 1.82, Middle East: 3.56, pooled: 1.75. ARMS2 A69S genotype OR/CFH Y402H genotype OR (heterogeneous genotypes): Asia = 0.93, Europe: 1.39, America: 2.06, Middle East: 1.20, pooled: 1.21. ARMS2 A69S risk genotypes have stronger predisposing effect on neovascular AMD compared to CFH Y402H risk genotypes.
Our inclusion criteria to select those studies which have analyzed the effect of these two loci in the same case-control samples showed much stronger effect of ARMS2 A69S in neovascular AMD compared to the CFH Y402H.
我们开展这项荟萃分析，以汇总那些在相同样本中同时分析CFH（Y402H或I62V）和ARMS2 A69S的研究，比较CFH和ARMS2在新生血管性年龄相关性黄斑变性（neovascular AMD）中的作用。
分别检索和回顾相关研究，以选择纳入的研究。纳入的研究具有ARMS2 A69S和CFH研究组的基因型数据。为了调整变量中的异质性，我们使用随机效应模型。使用STATA进行荟萃分析。采用漏斗图和Egger回归检验评估可能的发表偏倚。
总体而言，我们纳入了6676例新生血管性AMD病例和7668例对照。新生血管性AMD/对照的合并总体比值比（OR）（95%可信区间）为：ARMS2 A69S：GT与GG相比，OR = 2.35（2.01 - 2.75）；TT与GG相比，OR = 8.57（6.91 - 10.64）；CFH Y402H：CT与TT相比，OR = 1.94（1.73 - 2.18）；CC与TT相比，OR = 4.89（3.96 - 6.05）。ARMS2 A69S基因型OR/CFH Y402H基因型OR（同质基因型）：亚洲 = 2.14，欧洲：1.87，美洲：1.82，中东：3.56，合并：1.75。ARMS2 A69S基因型OR/CFH Y402H基因型OR（异质基因型）：亚洲 = 0.93，欧洲：1.39，美洲：2.06，中东：1.20，合并：1.21。与CFH Y402H风险基因型相比，ARMS2 A69S风险基因型对新生血管性AMD的易患作用更强。
我们选择那些在相同病例对照样本中分析这两个基因座作用的研究的纳入标准显示，与CFH Y402H相比，ARMS2 A69S在新生血管性AMD中的作用更强。
